Thus, these data suggest that pharmacological inhibitors of ERK5 can be exploited to target Wnt-driven intestinal tumour cell proliferation, and may be superior over MEK1/2 inhibitors in CRC tumours depending on KRAS mutation status. This evidence concerns the gene MAP2K1 and intestinal neoplasm.